Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells

Kim, Tae Sung; Cohen, Edward P.

doi:10.1038/sj.cgt.7700853

Cited by 10 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer-associated fibroblasts of the TME are vaccine targets as well. However, cancer-associated fibroblast vaccine strategies are all in the preclinical stage ( 45 – 47 ). Mads Hald Andersen et al.…”

Section: Spectrum Of Vaccine Targetsmentioning

confidence: 99%

Recent Progress on Therapeutic Vaccines for Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward.

show abstract

Section: Spectrum Of Vaccine Targetsmentioning

confidence: 99%

Recent Progress on Therapeutic Vaccines for Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This resulted in increased anti-tumor response and overall survival. The other CAF-related strategy employs allogenic fibroblasts transfected to express TAAs to promote immune response [191,192]. Essentially, immune-stimulatory CAFs are engineered to present tumor antigens and initiate a pro-inflammatory anti-tumorigenic environment.…”

Section: Cafsmentioning

confidence: 99%

The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines

Gordon

Gadi

2020

Vaccines

View full text Add to dashboard Cite

Breast cancer affects roughly one in eight women over their lifetime and is a leading cause of cancer-related death in women. While outcomes have improved in recent years, prognosis remains poor for patients who present with either disseminated disease or aggressive molecular subtypes. Cancer immunotherapy has revolutionized the treatment of several cancers, with therapeutic vaccines aiming to direct the cytotoxic immune program against tumor cells showing particular promise. However, these results have yet to translate to breast cancer, which remains largely refractory from such approaches. Recent evidence suggests that the breast tumor microenvironment (TME) is an important and long understudied barrier to the efficacy of therapeutic vaccines. Through an improved understanding of the complex and biologically diverse breast TME, it may be possible to advance new combination strategies to render breast carcinomas sensitive to the effects of therapeutic vaccines. Here, we discuss past and present efforts to advance therapeutic vaccines in the treatment of breast cancer, the molecular mechanisms through which the TME contributes to the failure of such approaches, as well as the potential means through which these can be overcome.

show abstract

Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma—A new vaccination strategy

Chopra

Kim

O-Sullivan

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

We report a new vaccination strategy for squamous cell carcinoma (SCC). The vaccine was prepared by transfer of unfractionated DNA-fragments (25 kb) from squamous carcinoma cells (KLN205, DBA/2 origin (H-2 d )) into LM mouse fibroblasts (C3H/ He origin; H-2 k ), a highly immunogenic cell line. To enhance their nonspecific immunogenic properties, the fibroblasts were modified before DNA transfer to secrete IL-2 and to express additional allogeneic MHC class I determinants. As the transferred DNA integrates into the genome of the recipient cells, and is replicated as the cells divide, sufficient DNA to prepare the vaccine could be obtained from as few as 10 7 squamous carcinoma cells (4 mm tumor). Since only a small proportion of the transfected cell-population was expected to have incorporated genes specifying antigens associated with the squamous carcinoma cells (TAA), we devised a novel approach to enrich the vaccine for cells that induce immunity to the SCC.Aliquots of the transfected population were divided into 10 small pools (initial inoculums 5 1 3 10 3 ). We reasoned that if the starting inoculums were sufficiently small, then the distribution of highly immunogenic and weakly immunogenic cells in each pool would not be the same. Cells from individual pools were allowed to increase in number. A portion of the expanded cell populations were maintained frozen/viable for later recovery. The remaining portions were used to immunize na€ ıve DBA/2 mice. Pools containing greater numbers of immunogenic cells were identified by 2 independent assays. Frozen aliquots of cells from the pool that stimulated immunity to the squamous carcinoma to the greatest extent were recovered and subdivided for additional rounds of immune selection. Enhanced immunity to squamous carcinoma mediated by CD81 T cells was induced in tumor-bearing mice treated solely by immunization with the enriched cell-population. ' 2006 Wiley-Liss, Inc.

show abstract

Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells

Cited by 10 publications

References 36 publications

Recent Progress on Therapeutic Vaccines for Breast Cancer

Recent Progress on Therapeutic Vaccines for Breast Cancer

The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines

Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma—A new vaccination strategy

Contact Info

Product

Resources

About